ArticleOncoTargets and therapy2021

Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.

Kang-Xin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.